Advertisement
YOU ARE HERE: LAT HomeCollectionsVimrx Pharmaceuticals Inc
IN THE NEWS

Vimrx Pharmaceuticals Inc

FEATURED ARTICLES
BUSINESS
September 29, 1998 | Barbara Marsh
The Irvine unit of Delaware-based VIMRX Pharmaceuticals Inc. agreed to buy assets of a competitor that lost a patent infringement lawsuit. VIMRX's Nexell Therapeutics unit--owned 80% by its Delaware parent and 20% by Baxter Healthcare Corp.--said it will exchange $3 million in VIMRX stock for certain assets of CellPro Inc., of Bothell, Wash. The assets include intellectual property, patents, research, licenses and related items.
ARTICLES BY DATE
BUSINESS
May 11, 1999 | GREG HERNANDEZ, TIMES STAFF WRITER
A biotechnology company said Monday that it will move to Irvine from Wilmington, Del., changing its name and teaming up with a local health care company to develop cell therapies to treat cancer. The move by VIMRx Pharmaceuticals Inc. will create 120 jobs, although many positions will be offered to current employees who choose to move to Irvine, the company said. VIMRx also will become known as Nexell Therapeutics Inc., an Irvine subsidiary.
Advertisement
BUSINESS
May 11, 1999 | GREG HERNANDEZ, TIMES STAFF WRITER
A biotechnology company said Monday that it will move to Irvine from Wilmington, Del., changing its name and teaming up with a local health care company to develop cell therapies to treat cancer. The move by VIMRx Pharmaceuticals Inc. will create 120 jobs, although many positions will be offered to current employees who choose to move to Irvine, the company said. VIMRx also will become known as Nexell Therapeutics Inc., an Irvine subsidiary.
BUSINESS
September 29, 1998 | Barbara Marsh
The Irvine unit of Delaware-based VIMRX Pharmaceuticals Inc. agreed to buy assets of a competitor that lost a patent infringement lawsuit. VIMRX's Nexell Therapeutics unit--owned 80% by its Delaware parent and 20% by Baxter Healthcare Corp.--said it will exchange $3 million in VIMRX stock for certain assets of CellPro Inc., of Bothell, Wash. The assets include intellectual property, patents, research, licenses and related items.
BUSINESS
December 19, 1997 | Dow Jones
Vimrx Pharmaceuticals Inc. and Baxter Healthcare Corp. said they have formed a new cell-therapy company that will be based in Irvine. Baxter provided $30 million and Vimrx $10 million to the new company's working capital. The companies said Vimrx acquired Baxter's immunotherapy unit and transferred the unit's assets to the new company. The companies had announced plans in July for the new venture. They expect to announce a name for the venture in early 1998.
BUSINESS
December 15, 1998 | Times Wire Services
A bankruptcy court has approved the sale of certain assets of CellPro Inc., which filed for bankruptcy after losing a patent infringement lawsuit, to an Irvine subsidiary of Delaware-based VIMRx Pharmaceuticals Inc., the VIMRx unit announced Monday. VIMRx's Nexell Therapeutics unit--owned 80% by its Delaware parent and 20% by Baxter Healthcare Corp.--previously agreed to acquire such CellPro assets as intellectual property, patents, research and licenses for $3 million in VIMRx stock.
BUSINESS
June 13, 2001 | MARC BALLON, TIMES STAFF WRITER
Struggling Nexell Therapeutics Inc. said Tuesday that it will fire two-thirds of its work force and transfer rights to its cell-processing products to its biggest shareholder, Baxter International Inc. The Irvine developer of cell therapies to treat cancer and other diseases said Baxter's health care unit will obtain worldwide sales and marketing and distribution rights for Nexell's flagship Isolex magnetic cell-selection system, cell culture and storage containers, and other products.
BUSINESS
May 6, 2000 | SYLVIA PAGAN WESTPHAL, TIMES STAFF WRITER
Nexell Therapeutics Inc. led the biotech industry's gainers Friday, as its shares soared 55% upon news that the Irvine company's product was one of the key components in the groundbreaking gene therapy trial reported by researchers last week. French scientists reported using gene therapy to treat three babies with "bubble boy disease," a rare inherited disorder that keeps newborns from developing a complete immune system.
BUSINESS
May 6, 2000 | SYLVIA PAGAN WESTPHAL, TIMES STAFF WRITER
Nexell Therapeutics shares soared 55% Friday on news that the Irvine-based biotech company's product was one of the key components in a groundbreaking gene therapy trial reported by researchers last week. French scientists reported using gene therapy to treat three babies with "bubble boy disease," a rare inherited disorder that keeps newborns from developing a complete immune system.
BUSINESS
June 13, 1997 | BARBARA MARSH, TIMES STAFF WRITER
Baxter International Inc. said it will spin off an Irvine-based medical research division, forming a new venture with a small Delaware biotech company to develop treatments for cancer, AIDS and other diseases. Vimrx Pharmaceuticals Inc. of Wilmington would own a controlling stake in the new company, which would be located in Irvine.
Los Angeles Times Articles
|